Canaccord raised the firm's price target on AtaiBeckley to $17 from $15 and keeps a Buy rating on the shares. The firm updatedits model after the company announced it has dosed the last patient in its Elumina Phase 2 trial for VLS-01 (DMT buccal film) for treatment-resistant depression (TRD), and reiterated its timeline for top-line data in 4Q26. Based on the data, the company now expects to advance VLS-01 into Phase 3 trials for major depressive disorder (MDD) following which it could expand into generalized anxiety disorder (GAD).
